News
AKESF
10.65
NaN%
--
Summit initiates, opens of trial sites of Phase II study of ivonescimab
TipRanks · 5d ago
Akeso Raises HK$1.94 Billion Through Institutional Share Placing
TipRanks · 10/16 09:24
Akeso to Raise HK$1.94 Billion via Discounted Share Placing
TipRanks · 10/13 22:37
Akeso announces first patient dosed in Phase III study of cadonilimab
TipRanks · 10/11 19:10
Akeso, Inc. (9926) Receives a Hold from Bernstein
TipRanks · 10/10 00:25
UBS Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 10/01 00:25
Chinese biopharma stocks rally as U.S. signals openness to drug licensing
Seeking Alpha · 09/21 09:37
HSBC Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 09/18 00:25
CICC Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 09/17 05:25
Akeso, Inc. (9926) Gets a Buy from SPDB
TipRanks · 09/16 05:15
UBS Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 09/15 05:15
CLSA Sticks to Its Buy Rating for Akeso, Inc. (9926)
TipRanks · 09/15 00:15
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Seeking Alpha · 09/13 17:23
SDIC Securities Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 09/06 05:05
CICC Keeps Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 09/04 05:06
Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results
TipRanks · 09/03 15:48
Akeso, Inc. (9926) Gets a Buy from UBS
TipRanks · 09/03 13:45
Akeso’s Ivonescimab Tops Pembrolizumab in Key Lung Cancer Survival Trial
TipRanks · 09/02 23:08
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
Seeking Alpha · 09/02 22:09
Akeso, Inc. (9926) Gets a Buy from Huatai Securities
TipRanks · 09/01 05:06
More
Webull provides a variety of real-time AKESF stock news. You can receive the latest news about Akeso through multiple platforms. This information may help you make smarter investment decisions.
About AKESF
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.